Dado oficial do USPTO

STARPAX

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Ativar vigilância desta marca Falar com especialista

Snapshot rápido

STARPAX

ST13

US500000088423029

Classe

1, 5, 42, 44

Pedido

88423029

Registro

7797794

Ver no USPTO

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

Atualização mais recente

03/04/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

1, 5, 42, 44

Data de depósito

09/05/2019

Data de registro

20/05/2025

Data de expiração

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

20/05/2025

Última transação

03/04/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

700

Cadastro oficial

Principal Register

Fundamento do pedido

Intent to use, Foreign priority

Código do desenho

Tipo de titular

Localização do titular

MONTRÉAL, CA

Examinador

WHEATLEY, TRAVIS DWIGHT

Unidade examinadora

O10

Localização atual

FILE REPOSITORY (FRANCONIA)

Titulares e representantes

Titulares

STARPAX BIOPHARMA INC.

Starpax Medical Inc.

Representantes

Alison M. Caless CANTOR COLBURN LLP

Classificação técnica

Classes Nice

Classe 1Classe 5Classe 42Classe 44

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 1

active biochemical formulations in the nature of active biochemical ingredients for use in the manufacture of anti-cancer drugs

Classe 5

anti-cancer preparations; bacteria capable to transport therapeutic agents and imagery markers into cancer tumors and organs for the treatment of cancer and other diseases requiring targeted delivery; bacteria capable to transport therapeutic agents and imagery markers into organs for the treatment of diseases or disorders located in low oxygen areas of the human body and the animal body; pharmaceutical preparations and compositions for the treatment and prevention of cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; pharmaceutical preparations and substances for the treatment of cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; therapeutic agents and imagery markers for delivery of cancer treatment

Classe 42

Pharmaceutical research and development; medical and scientific researchconducting clinical trials for others for pharmaceutical preparations used for the treatment of cancerimmunologicalinflammatory and infectious diseasespain

Classe 44

Health care services for treating cancer and diseases or disorders located in low oxygen areas of the human body and the animal body; medical analysis services for cancer diagnosis and prognosis; medical diagnostic services

Publicações

Histórico de despachos e eventos da marca no USPTO.

51 publicações encontradas

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

20/05/2025

R.PR

REGISTERED-PRINCIPAL REGISTER

20/05/2025

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

01/04/2025

PUBO

PUBLISHED FOR OPPOSITION

01/04/2025

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

26/03/2025

LAW OFFICE PUBLICATION REVIEW COMPLETED

12/03/2025

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

11/03/2025

XAEC

EXAMINER'S AMENDMENT ENTERED

10/03/2025

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

10/03/2025

GNEA

EXAMINERS AMENDMENT E-MAILED

10/03/2025

CNEA

EXAMINERS AMENDMENT -WRITTEN

10/03/2025

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

06/03/2025

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

06/03/2025

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

06/03/2025

GNS2

NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED

12/01/2025

GNSI

INQUIRY TO SUSPENSION E-MAILED

12/01/2025

CNSI

SUSPENSION INQUIRY WRITTEN

12/01/2025

RCCK

SUSPENSION CHECKED - TO ATTORNEY FOR ACTION

06/01/2025

ASGN

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

25/09/2024

DOCK

ASSIGNED TO EXAMINER

15/08/2024

RCCK

SUSPENSION CHECKED - TO ATTORNEY FOR ACTION

15/08/2024

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

27/11/2023

GNSL

LETTER OF SUSPENSION E-MAILED

27/11/2023

CNSL

SUSPENSION LETTER WRITTEN

27/11/2023

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

27/11/2023

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

27/11/2023

ALIE

ASSIGNED TO LIE

26/11/2023

ERSI

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

21/06/2023

GNS2

NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED

17/04/2023

GNSI

INQUIRY TO SUSPENSION E-MAILED

17/04/2023

CNSI

SUSPENSION INQUIRY WRITTEN

17/04/2023

RCCK

SUSPENSION CHECKED - TO ATTORNEY FOR ACTION

13/04/2023

DOCK

ASSIGNED TO EXAMINER

11/04/2023